Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3411798 | 0.78 | TYR (0.36) | ADRB3HSD17B1HSD17B2 | |
| SCHEMBL1733618 | 0.76 | NPC1 (0.47) | DAO | |
| SCHEMBL3413575 | 0.76 | OXTR (0.37) | ACACBADRB3HSD17B1HSD17B2 | |
| SCHEMBL2978394 | 0.73 | CALM1 (0.51) | — | |
| SCHEMBL23043090 | 0.69 | TRPA1 (0.47) | — | |
| SCHEMBL3602439 | 0.69 | CHRNB2 (0.47) | — | |
| SCHEMBL30639497 | 0.69 | CHRNB2 (0.47) | — | |
| SCHEMBL1853092 | 0.68 | AKR1B1 (0.48) | — | |
| SCHEMBL30576431 | 0.68 | AKR1B1 (0.48) | — | |
| SCHEMBL3435210 | 0.68 | ESR1 (0.68) | DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8715761-B2 | Flavor molecules | GIVAUDAN S.A. (CH) | 2014-05-06 | — | — | US | disclosed |
| US-8449936-B2 | Flavor molecules | GIVAUDAN SA (CH) | 2013-05-28 | — | — | US | disclosed |
| EP-2259689-B1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2011-11-16 | — | — | EP | disclosed |
| EP-2259689-A1 | FLAVOR MOLECULES | Givaudan SA (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-20100272656-A1 | Flavor Molecules | GIVAUDAN SA (CH) | 2010-10-28 | — | — | US | disclosed |
| US-20100040753-A1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2010-02-18 | — | — | US | disclosed |
| WO-2009105906-A1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272656-A1 | Flavor Molecules | TAS2R30, TAS2R31, TAS2R1 | DAO 2524/4885ACACB 1562/4885ADRB3 1903/4885 |
| US-20100040753-A1 | FLAVOR MOLECULES | TAS2R30, TAS2R31, TAS2R1 | DAO 2524/4885ACACB 1562/4885ADRB3 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.